Diagnosing Cancer in the Symptomatic Patient

Salzman, Brooke; Lamb, Kathleen M.; Olszewski, Robert F.; Tully, Amber; Studdiford, James

doi:10.1016/j.pop.2009.07.005

Cited by 9 publications

(6 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is interesting that in our study, both weight gain and weight loss loaded on both the GI and the nutritional symptom clusters. While weight loss is often associated with a cancer diagnosis (Salzman et al, 2009) and its treatment,(Pedersen et al, 2016) patients with breast cancer report that weight gain can be a significant problem (Nyrop et al, 2016; Wolin et al, 2010). Patients in this study had a BMI of 26.24 (±5.81), which is categorized as overweight by the Centers for Disease Control (Centers et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy

Sullivan

Leutwyler

Dunn

et al. 2017

European Journal of Oncology Nursing

View full text Add to dashboard Cite

Purpose One of the unanswered questions in symptom clusters research is whether the number and types of symptom clusters vary based on the dimension of the symptom experience used to create the clusters. Given that patients with breast cancer receiving chemotherapy (CTX), report between 10 and 32 concurrent symptoms and studies of symptom clusters in these patients are limited, the purpose of this study, in breast cancer patients undergoing CTX (n=515), was to identify whether the number and types of symptom clusters differed based on whether symptom occurrence rates or symptom severity ratings were used to create the clusters. Methods A modified version of the Memorial Symptom Assessment Scale was used to assess for the occurrence and severity of 38 symptoms, one week after the administration of CTX. Exploratory factor analysis was used to extract the symptom clusters. Results Both the number and types of symptom clusters were similar using symptom occurrence rates or symptom severity ratings. Five symptom clusters were identified using symptom occurrence rates (i.e., psychological, hormonal, nutritional, gastrointestinal, epithelial). Six symptom clusters (i.e., psychological, hormonal, nutritional, gastrointestinal, epithelial, chemotherapy neuropathy) were identified using symptom severity ratings. Across the two dimensions, the specific symptoms within each of the symptom clusters were similar. Conclusions Identification of symptom clusters in patients with breast cancer may be useful in guiding symptom management interventions. Future studies are warranted to determine if symptom clusters remain stable over a cycle of CTX in patients with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy

Sullivan

Leutwyler

Dunn

et al. 2017

European Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…Cancers are often found by symptomatic presentation, which may manifest as a breast lump, rectal bleeding, persistent cough, lymphadenopathy and weight loss [14]. Indeed, in many cases, the patient remains asymptomatic and thus no medical treatment is sought.…”

Section: Early Detection Is Criticalmentioning

confidence: 99%

On the Need for the Development of a Cancer Early detection, diagnostic, prognosis, and Treatment Response System

Tobore

2019

Future Sci. OA

View full text Add to dashboard Cite

Cancer is the second leading cause of noncommunicable disease deaths in the world. In 2018, there were over 18 million new cancer cases and approximately 10 million people died from the disease globally. In 2019, almost two million new cases of cancer will be diagnosed in USA and over 600,000 people are expected to die from the disease. The incidence of cancer is expected to rise because of lifestyle changes and a rapidly aging population. Evidence suggests that early detection is critical to reducing cancer morbidity and mortality. In this paper, the development of an integrated smart wearable and biomarker detection system is proposed to help reduce cancer morbidity and mortality. The potential benefits and limitations of the system are discussed.

show abstract

“…Większość limfadenopatii u dzieci ma charakter łagodny, w tym najczęściej infekcyjny. U dorosłych i u dzieci limfadenopatia utrzymująca się bez zmiany wielkości węzła raczej nie ma charakteru nowotworowego [4,6], a wyjątki to HL niskiego stopnia (Hodgkin Lymphoma low grade) oraz postaci indolentne NHL (non-Hodgkin lymphoma), chociaż w obydwu przypadkach zazwyczaj występują towarzyszące objawy systemowe [7].…”

Section: Czas Trwania Limfadenopatiiunclassified

Limfadenopatia u dzieci i dorosłych: zasady postępowania diagnostycznego

Styczyński

2019

Acta Haematologica Polonica

View full text Add to dashboard Cite

StreszczeniePowiększenie węzłów chłonnych (limfadenopatia) jest jednym z najczęstszych objawów klinicznych, zwłaszcza u dzieci. U ok. 50% zdrowych dzieci dochodzi do powiększenia węzłów chłonnych; najczęściej w wieku 2-10 lat. Celem pracy jest przedstawienie zasad postępowania diagnostycznego u pacjenta z limfadenopatią, jak również omówienie jej przyczyn, zasad rozpoznawania oraz przedstawienie rekomendacji postępowania klinicznego u pacjenta z powiększeniem węzłów chłonnych. Etiologię limfadenopatii u dzieci i dorosłych oraz związane z tym ukierunkowanie diagnostyki różnicowej można określić wg kilku reguł przedstawionych akronimami w języku angielskim: MIAMI, CHICAGO, wg liter alfabetu lub lokalizacji. W postępowaniu diagnostycznym obowiązuje czteroetapowy proces: (1) badanie podmiotowe (wywiad) i przedmiotowe; na tym etapie najczęściej zapada decyzja o hospitalizacji; (2) badania laboratoryjne; (3) badania obrazowe: USG i/lub tomografia komputerowa; (4) otwarta biopsja węzła. W chwili obecnej otwarta biopsja węzła i badanie histopatologiczne są złotym standardem diagnostycznym limfadenopatii u dzieci. Ze względu na ryzyko maskowania lub opóźnienia rozpoznania chłoniaka lub białaczki do czasu ustalenia jednoznacznej diagnozy nie należy podawać steroidów. U dzieci z ostrym jednostronnym powiększeniem przednich węzłów chłonnych szyjnych oraz z objawami ogólnymi powinna zostać zastosowana antybiotykoterapia empiryczna.

show abstract

Diagnosing Cancer in the Symptomatic Patient

Cited by 9 publications

References 62 publications

Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy

Differences in symptom clusters identified using symptom occurrence rates versus severity ratings in patients with breast cancer undergoing chemotherapy

On the Need for the Development of a Cancer Early detection, diagnostic, prognosis, and Treatment Response System

Limfadenopatia u dzieci i dorosłych: zasady postępowania diagnostycznego

Contact Info

Product

Resources

About